Private Equity and Medicine: Top Firms in 2026

Key Facts

• PE investment in healthcare grew from $5 billion in 2000 to an estimated $104 billion in 2024, a 20-fold increase over two decades.
• The decade from 2010 to 2020 saw $750 billion in total PE capital deployed across healthcare services, physician practices, and hospital systems.
• Private equity firms owned 5,779 physician practices in 2021, up from 816 in 2012, a 600% increase in nine years.
• Nearly 460 U.S. hospitals were under PE control as of early 2024, representing 22% of all private for-profit hospitals.
• Lower middle market funds with less than $500 million in AUM account for 73.7% of all physician practice acquisitions in the most-studied specialties.
• Of practices that exited PE ownership between 2016 and 2020, 97.8% were resold to another PE firm rather than to a hospital system or strategic buyer.
• PE-backed platforms grew an average of 595% in affiliated practice sites in approximately three years between initial investment and exit.

Healthcare Private Equity Overview

PE investment in medicine encompasses the acquisition, restructuring, and resale of healthcare entities. Private equity firms target internal rates of return (IRR) exceeding 20% annually within three to seven years. The asset class spans physician practices across more than a dozen specialties, hospital systems, nursing homes, hospices, fertility clinics, and emergency medicine staffing companies.

Venture capital, a subset of PE focused on early-stage companies, occasionally invests in medical technology but rarely targets physician practices directly. The dominant deal structure is the leveraged buyout (LBO). A general partner (GP) acquires a healthcare entity using debt-to-equity ratios as high as 7:1, placing that debt on the acquired organization rather than on the fund.

The GP then executes a roll-up strategy. Starting with a platform acquisition, the fund builds market share through serial add-on acquisitions of smaller practices. Multiple arbitrage at exit drives returns for limited partners (LPs): the enlarged platform sells at a higher earnings multiple than the entry price.

Bain Capital, KKR, and Warburg Pincus have all operated in the broader healthcare space. The most documented physician practice consolidation involves Welsh Carson Anderson and Stowe, Cerberus Capital Management, Blackstone Group, and Audax Private Equity. A cluster of lower middle market specialists uses management services organizations (MSOs) to aggregate practices while navigating corporate practice of medicine laws.

Geographically, PE activity in medicine concentrates in Texas, Florida, California, Massachusetts, Georgia, and Pennsylvania. Texas stands out for anesthesiology consolidation: Welsh Carson Anderson and Stowe's US Anesthesia Partners controlled 70% of the Houston anesthesiology market by 2021. Massachusetts became the center of the decade's most prominent hospital PE story after Steward Health Care filed Chapter 11 bankruptcy in May 2024.

Eleven states enacted advance notice or prior approval laws for healthcare transactions by 2025. Massachusetts and Oregon led these reforms, reflecting growing regulatory scrutiny of PE deal flow in medicine.

Healthcare PE Firms: Comparison Table

Twelve active PE firms dominate the current landscape across five medical specialties. Fund size tiers range from lower middle market (under $500 million) to large cap (more than $5 billion). Most firms do not publicly disclose AUM figures; the table uses fund size tier as the primary reference, supplemented by platform company data.

Lower middle market funds execute 73.7% of physician practice acquisitions by volume. Large-cap players like Blackstone operate at the hospital and staffing company level, where individual deal values are far higher and regulatory exposure is more severe. The absence of publicly disclosed AUM for most healthcare PE fund managers reflects deliberate opacity, a structural issue that state advance notice laws are designed to address.

Top Picks by Investment Strategy

Fastest Platform Growth: Shore Capital Partners built EyeSouth Partners from 5 to 155 practice sites in just 2.8 years, a 3,000% expansion representing the steepest platform growth among all studied PE firms in any specialty.

Most Active in Gastroenterology: Audax Private Equity's Gastro Health grew from 21 to 212 practice sites in 2.4 years, a 909.5% expansion. Waud Capital Partners' GI Alliance expanded from 70 to 308 sites in 3.3 years, making it the largest gastroenterology platform by absolute site count at exit.

Anesthesiology Consolidator: Welsh Carson Anderson and Stowe built US Anesthesia Partners into the dominant force in Texas anesthesiology, reaching 70% of the Houston market by 2021 before the FTC filed an antitrust suit in September 2023.

Largest Hospital System Deal: Cerberus Capital Management converted Caritas Christi Health Care into Steward Health Care and generated $800 million in profit before a 2020 exit. This remains the highest-return hospital PE transaction on record despite Steward's subsequent 2024 bankruptcy.

Dermatology Specialist: Chicago Pacific Founders' Pinnacle Dermatology grew 266.7% from 24 to 88 sites across 12 states in 2.6 years, one of the most geographically diverse dermatology platforms built by a lower middle market fund.

Opportunistic Rural Play: Kinderhook Industries acquired Steward's 5,000-physician network in 2024 at distressed pricing following the bankruptcy. The firm repositioned itself as the primary aggregator of large physician networks exiting failed PE or hospital ownership.

Upper Middle Market Ophthalmology: HIG Capital grew American Vision Partners from 40 to 92 sites over 4.6 years. That holding period is the longest among ophthalmology PE platforms, consistent with the more patient investment thesis typical of upper middle market ($1.5 billion to $5 billion) funds.

Top 10 Healthcare PE Firms in Detail

Welsh Carson Anderson and Stowe

Welsh Carson Anderson and Stowe provides the clearest example of the consolidator model in medicine. The firm built US Anesthesia Partners (USAP) through serial acquisitions across Texas beginning in 2012. By 2021, USAP held 70% of the Houston anesthesiology market; United Healthcare reimbursed USAP at rates 95% above the in-network Texas median.

The FTC filed an antitrust suit in September 2023. The suit alleged Welsh Carson orchestrated price-setting arrangements and market allocation agreements among competing anesthesiology groups. A January 2025 settlement barred the firm from increasing its USAP ownership stake.

Physicians evaluating offers in hospital-based specialties should treat the USAP case as the definitive regulatory benchmark for antitrust exposure in procedural medicine roll-ups.

Cerberus Capital Management

Cerberus executed the signature hospital PE transaction of the 2010s by acquiring Caritas Christi Health Care in 2010, converting the Massachusetts nonprofit network to for-profit status, and rebranding it as Steward Health Care. The firm arranged a $1.25 billion sale-leaseback with Medical Properties Trust in 2016, generating immediate capital while saddling Steward with inflated rent obligations. Cerberus distributed $800 million in profit and exited in 2020.

Subsequent management fell $50 million behind on rent by January 2024 and filed Chapter 11 bankruptcy in May 2024, with two hospitals closing permanently. Cerberus's Steward trajectory is the most-cited case study in congressional hearings on debt loading in hospital PE.

Blackstone Group

Blackstone operates at the intersection of large-cap private equity and physician staffing, a pairing that generates fund-scale deal flow while concentrating regulatory risk. Its primary healthcare vehicle, TeamHealth, became a central exhibit in congressional debates over surprise billing. In March 2020, TeamHealth removed emergency physician Dr. Ming Lin from his rotation in Washington State after he publicly raised COVID-19 safety concerns.

Blackstone's healthcare investments operate within funds exceeding $5 billion. This places it among the handful of PE investors with the capital to acquire entire hospital-based physician groups rather than assembling them through individual add-on transactions.

Audax Private Equity

Among gastroenterology PE platforms, Audax achieved the highest growth rate on record: Gastro Health expanded from 21 to 212 practice sites in just 2.4 years, a 909.5% increase. Audax operates in the middle market with fund sizes between $500 million and $1.5 billion, providing more capital than the lower middle market while maintaining flexibility for rapid add-on acquisitions. Gastro Health expanded from a single-state Florida base to operations in Alabama, Maryland, Ohio, Virginia, and Washington before exit.

This demonstrates how a middle market fund can build national specialty platforms faster than any hospital system. The roll-up strategy aggregates independently recruited gastroenterologists rather than developing practices from scratch.

Shore Capital Partners

Shore Capital Partners built EyeSouth Partners from 5 practice sites to 155 in 2.8 years, a 3,000% growth rate unmatched by any PE firm in any specialty in the studied dataset. Operating as a lower middle market fund with under $500 million in AUM, Shore proved that the roll-up strategy generates outsized returns without large-cap capital. EyeSouth expanded from a single Georgia base to 11 states by exit.

The 2.8-year holding period tracks precisely with the 2.9-year median documented across all physician practice PE exits in dermatology, ophthalmology, and gastroenterology. LPs benchmarking lower middle market healthcare performance use EyeSouth as the upper-bound return case.

Leonard Green & Partners

Leonard Green acquired Prospect Medical Holdings in 2010 for $363 million, entering a California-based five-hospital system. The firm distributed more than $500 million to investors between 2012 and 2020 as Prospect expanded to 16 hospitals across five states. Prospect's financial liabilities grew from $451 million in 2015 to $1.6 billion by 2019 as Leonard Green extracted capital from the portfolio company.

Prospect filed Chapter 11 bankruptcy in January 2025 with $2.3 billion in debt. The closure of Crozer Health in Pennsylvania alone cost more than 2,600 jobs. Leonard Green's Prospect trajectory is the most frequently cited example of investor distributions structurally preceding facility failure in hospital PE.

Chicago Pacific Founders

Chicago Pacific Founders built Pinnacle Dermatology from 24 sites in three states to 88 sites across 12 states in 2.6 years, a 266.7% expansion that ranks among the most geographically diverse dermatology platforms built by a lower middle market fund. Dermatology attracts fund managers below $500 million because aesthetic procedures are non-covered and fully cash-pay, insulating revenue from Medicare reimbursement rate cuts while high procedure volume supports EBITDA expansion. Pinnacle's geographic arc from Illinois, Indiana, and Michigan into Arizona, Virginia, Tennessee, and Texas shows how a sub-$500 million fund can build national scale through add-on acquisitions.

Waud Capital Partners

Waud Capital's GI Alliance grew from 70 to 308 practice sites in 3.3 years, expanding from Texas and Louisiana origins to 14 states including Arkansas, Colorado, and Washington. That 340% expansion made GI Alliance the largest gastroenterology platform by site count among PE-backed portfolios in the studied dataset. GI Alliance concentrated initial market power along the Gulf Coast before executing multistate expansion, distinguishing its approach from Audax's Gastro Health, which launched from a single-state base.

Gastroenterology attracts investment at multiple fund tiers because colonoscopy and endoscopy procedure volume is predictable, reimbursed at above-average Medicare rates, and less sensitive to macroeconomic conditions than elective surgical specialties.

HIG Capital

HIG Capital built American Vision Partners from 40 to 92 ophthalmology sites over 4.6 years, the longest holding period among ophthalmology PE platforms in the studied data. The 130% growth rate falls below the ophthalmology peer average. It reflects a more measured accumulation timeline suited to a larger fund with less pressure to exit quickly to smaller secondary buyers.

American Vision Partners expanded from Arizona and New Mexico into California, Nevada, and Texas. HIG, headquartered in Miami and operating in the upper middle market ($1.5 billion to $5 billion), offers LP allocators a hold period more consistent with a traditional buyout fund model than the 2.8-year ophthalmology exits common among lower middle market players.

Kinderhook Industries

Kinderhook's 2024 acquisition of Steward Health Care's 5,000-physician network, rebranded as Revere Medical through its Rural Healthcare Group vehicle, represents the newest pattern in healthcare PE: distressed physician network acquisition following hospital system bankruptcy. Rather than building a platform through individual add-on purchases, Kinderhook acquired an already-assembled network at distressed pricing from a bankruptcy estate. This opportunistic model mirrors the secondary buyout dynamic documented across specialty practices, with the added distinction that the seller was a bankruptcy trustee rather than another PE fund.

Rural and community physician networks, stripped from failing hospital systems, constitute a growing acquisition target as PE scrutiny tightens in urban specialty markets.

Investment Trends Shaping Healthcare PE

Secondary Buyouts as the Dominant Exit Route

Of 417 physician practice PE exits between 2016 and 2020 in the three most-studied specialties, 97.8% were resales to another PE firm. Practices typically moved from lower middle market funds (under $500 million) to middle, upper middle, or large cap buyers in successive transactions. This PE-to-PE perpetuation cycle means physician practices can cycle through multiple short-term owners without ever reaching a strategic buyer who intends to hold them long-term, compounding clinical instability across ownership transitions.

Specialty Concentration and Antitrust Exposure

Anesthesiology, emergency medicine, and pathology attract PE because patients cannot choose their provider, enabling out-of-network billing and above-median reimbursement rates. USAP's 70% Houston anesthesiology market share and Blackstone's TeamHealth controversy accelerated FTC enforcement and the No Surprises Act. At least 11 states now require advance notice for healthcare transactions, with Massachusetts and Oregon enacting the most comprehensive restrictions in 2025, including Massachusetts banning sale-leaseback arrangements in hospital real estate transactions.

Nonprofit Hospital Targeting

PE firms historically targeted for-profit hospital conversions, but evidence as of 2025 indicates nonprofit health systems are increasingly vulnerable to MSO-based acquisition structures. Cerberus's Steward trajectory established the template regulators now cite: nonprofit acquisition, sale-leaseback, $800 million in profits extracted, then Chapter 11 bankruptcy with permanent hospital closures. Massachusetts's 2025 law expanded PE transaction notice requirements specifically in response to nonprofit hospital exposure.

Emerging Specialties Beyond the Core Three

Behavioral health, primary care, urology, oncology, and fertility clinics represent the next wave of roll-up targets beyond dermatology, gastroenterology, and ophthalmology. COVID-19 accelerated financial stress among independent practices, expanding the pool receptive to acquisition offers. Growing administrative burden continues to push solo and small-group practices toward PE acquisition despite documented risks to clinical autonomy and staffing levels post-acquisition.

Regulatory Pressure and Structural Workarounds

Growing FTC scrutiny and state-level disclosure requirements are reshaping deal structure rather than reducing dry powder deployment into healthcare. PE firms increasingly use MSOs to separate administrative ownership from clinical employment, circumventing corporate practice of medicine (CPOM) laws in states including California. Most physician practice acquisitions fall below Hart-Scott-Rodino Act reporting thresholds, allowing serial consolidation to proceed without mandatory antitrust review.

The FTC's USAP action was notable precisely because it targeted a completed roll-up that had achieved 70% market concentration through individually sub-threshold transactions.

How to Evaluate Healthcare PE Firms

Track record on portfolio companies is the primary criterion for both physicians considering acquisition offers and fund managers evaluating co-investment opportunities. A firm's history of facility closures, bankruptcy involvement, or FTC actions should raise immediate concerns regardless of headline purchase price. Cerberus made $800 million on Steward; Leonard Green distributed $500 million from Prospect. Both portfolios subsequently filed for bankruptcy, showing that PE investor returns and portfolio company outcomes can be structurally decoupled.

Fund size tier determines which practices a firm targets and how long it intends to hold. Lower middle market funds under $500 million, which execute 73.7% of physician practice acquisitions, exit via secondary buyout in a median of 2.9 years. A physician evaluating an offer from a sub-$500 million fund should anticipate that clinical conditions will be renegotiated by a new owner within three years.

Debt loading and sale-leaseback terms deserve specific scrutiny. PE firms place debt-to-equity ratios of up to 7:1 on acquired entities. A sale-leaseback, like the $1.25 billion arrangement Steward signed with Medical Properties Trust, generates immediate cash for the acquiring fund while saddling the healthcare entity with rent obligations that outlast the firm's ownership period. Physicians and hospital administrators should request the acquisition's pro forma debt schedule and lease terms before signing any letter of intent.

Non-compete agreements are standard in PE-backed practice acquisitions and are set by the fund rather than by the platform management team a physician interacts with day to day. PE-owned practice physicians were 16.5 percentage points more likely to work elsewhere within two years of PE exit, and 44% of physicians in PE-backed practices stayed compared to 60% in comparable non-PE practices. Review the geographic scope and duration of any non-compete before closing.

Which Firm Fits Your Needs?

Physicians in procedure-heavy specialties who have received acquisition offers are most likely dealing with a lower middle market fund operating below $500 million. Shore Capital, Chicago Pacific Founders, Revelstoke Capital Partners, and Audax represent this tier or the adjacent middle market. The central question is not whether to sell, but what the exit terms mean for continued employment after the inevitable secondary buyout.

With 97.8% of PE healthcare exits going to another PE firm, physicians should plan for ownership to change within three years of signing. LPs evaluating healthcare PE exposure through fund-of-funds structures or direct commitments should examine secondary buyout concentration in the fund's portfolio history. A fund whose exits consist primarily of PE-to-PE resales has generated returns by passing assets up the fund-size ladder, not by improving operational performance.

Shore Capital's EyeSouth (3,000% growth) and Audax's Gastro Health (909% growth) represent the upper bound of platform-building returns achievable in lower and middle market healthcare. LPs seeking measured hold periods should examine upper middle market players like HIG Capital. Policymakers and hospital administrators in states with pending healthcare PE legislation should monitor serial acquisitions that fall below Hart-Scott-Rodino reporting thresholds, since the USAP case demonstrates that 70% market concentration is achievable through individually sub-threshold transactions.

Advisors working with independent physician practices should flag any offer from a firm with an active FTC action or a portfolio company that entered bankruptcy within the prior five years. Both are documented in public filings and searchable through state attorney general records.

Methodology

This article on private equity and medicine draws on publicly available academic research, government reports, Senate Budget Committee findings, and deal data from PE firm portfolio directories and press releases. Firm profiles reflect documented portfolio companies and growth metrics from studies published through early 2025. Market statistics reference the period 2010 through 2024, with 2024 figures noted as estimated where final data is unavailable. No AUM figures are cited for firms where verified public data was absent. The article includes firms based on documented deal activity in physician practice and hospital acquisitions across the most-studied medical specialties; no editorial compensation or commercial relationship influenced inclusion.